Endogenex
Minneapolis, US · Founded 2017 · 28 employees on LinkedIn · 6 known investors
Find your way into Endogenex
Sign up to see every warm intro you have to Endogenex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Endogenex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
Founders & leadership

Investors · 6
How we know: Arboretum Ventures's portfolio page · funding news · finance.yahoo.com · Not right? Tell us
How we know: Hatteras Venture Partners's portfolio page · Not right? Tell us
How we know: Intuitive Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: Longitude Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$50M disclosed across 1 of 3 rounds · 2024–2026
- $50MSeries C ExtensionMar 2026 · 3 sources
Arboretum Ventures (lead)
Source ↗ - Undisclosed amountSeries CJun 2024Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 4
Companies working in the same space as Endogenex.
In the news
Frequently asked questions
- What does Endogenex do?
- Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
- Who are Endogenex's investors?
- Endogenex's investors include Arboretum Ventures, Hatteras Venture Partners, Intuitive Ventures, Longitude Capital, Lumira Ventures, Southeast Minnesota Capital Fund.
- How much funding has Endogenex raised?
- Endogenex has disclosed $50M raised across 1 of its 3 known rounds.
- Where is Endogenex headquartered?
- Endogenex is headquartered in Minneapolis, US.







